This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Pharosgen Co., Ltd. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Seung Il Baek: Innovator in Doppel-Targeting Antibodies
Introduction
Seung Il Baek is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of doppel-targeting antibodies. His innovative work aims to address various diseases associated with pathological angiogenesis.
Latest Patents
Seung Il Baek holds 1 patent for his invention of doppel-targeting molecules, which are useful for inhibiting pathological angiogenesis. This patent describes antibodies that can treat conditions such as tumors, cancers, atherosclerosis, tuberculosis, asthma, and pulmonary arterial hypertension (PAH). The invention also includes methods for detecting doppel expression in subjects, showcasing its potential in both therapeutic and diagnostic applications.
Career Highlights
Seung Il Baek is currently associated with Pharosgen Co., Ltd., where he continues to advance his research in the field of biotechnology. His work has garnered attention for its potential impact on treating serious health conditions.
Collaborations
Seung Il Baek collaborates with notable colleagues, including Youngro Byun and Ha Kyeong Lee, who contribute to the innovative research environment at Pharosgen Co., Ltd.
Conclusion
Seung Il Baek's contributions to the field of doppel-targeting antibodies highlight his role as an influential inventor in biotechnology. His work not only addresses critical health issues but also paves the way for future innovations in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile